Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.

Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M.

Cancer Sci. 2017 Oct;108(10):1974-1984. doi: 10.1111/cas.13337. Epub 2017 Aug 29.

2.

HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.

Harashima N, Takenaga K, Akimoto M, Harada M.

Oncotarget. 2017 Jun 27;8(26):42887-42900. doi: 10.18632/oncotarget.17157.

3.

Identification of laminin α5 short arm peptides active for endothelial cell attachment and tube formation.

Kikkawa Y, Sugawara Y, Harashima N, Fujii S, Ikari K, Kumai J, Katagiri F, Hozumi K, Nomizu M.

J Pept Sci. 2017 Jul;23(7-8):666-673. doi: 10.1002/psc.2987. Epub 2017 Feb 21.

PMID:
28220599
4.

Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma.

Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.

Int Immunopharmacol. 2017 Mar;44:197-202. doi: 10.1016/j.intimp.2017.01.014. Epub 2017 Jan 19.

PMID:
28110220
5.

An Anti-Human Lutheran Glycoprotein Phage Antibody Inhibits Cell Migration on Laminin-511: Epitope Mapping of the Antibody.

Enomoto-Okawa Y, Maeda Y, Harashima N, Sugawara Y, Katagiri F, Hozumi K, Hui KM, Nomizu M, Ito Y, Kikkawa Y.

PLoS One. 2017 Jan 6;12(1):e0167860. doi: 10.1371/journal.pone.0167860. eCollection 2017.

6.

Age-associated impairment of antitumor immunity in carcinoma-bearing mice and restoration by oral administration of Lentinula edodes mycelia extract.

Ishikawa S, Matsui Y, Wachi S, Yamaguchi H, Harashima N, Harada M.

Cancer Immunol Immunother. 2016 Aug;65(8):961-72. doi: 10.1007/s00262-016-1857-y. Epub 2016 Jun 16.

PMID:
27312060
7.

Down-regulation of cell adhesion via rho-associated protein kinase (ROCK) pathway promotes tumor cell migration on laminin-511.

Kikkawa Y, Harashima N, Ikari K, Fujii S, Katagiri F, Hozumi K, Nomizu M.

Exp Cell Res. 2016 May 15;344(1):76-85. doi: 10.1016/j.yexcr.2016.04.002. Epub 2016 Apr 8.

PMID:
27068375
8.

Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer.

Cherkasova E, Scrivani C, Doh S, Weisman Q, Takahashi Y, Harashima N, Yokoyama H, Srinivasan R, Linehan WM, Lerman MI, Childs RW.

Cancer Res. 2016 Apr 15;76(8):2177-85. doi: 10.1158/0008-5472.CAN-15-3139. Epub 2016 Feb 9.

9.

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.

Hari Y, Harashima N, Tajima Y, Harada M.

Oncotarget. 2015 Dec 8;6(39):41902-15. doi: 10.18632/oncotarget.5881.

10.

Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.

Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.

J Immunother. 2015 Sep;38(7):285-91. doi: 10.1097/CJI.0000000000000090.

PMID:
26261892
11.

The Roles of ROS and Caspases in TRAIL-Induced Apoptosis and Necroptosis in Human Pancreatic Cancer Cells.

Zhang M, Harashima N, Moritani T, Huang W, Harada M.

PLoS One. 2015 May 22;10(5):e0127386. doi: 10.1371/journal.pone.0127386. eCollection 2015.

12.

New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.

Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco MA, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.

Int Immunopharmacol. 2015 May;26(1):133-8. doi: 10.1016/j.intimp.2015.03.023. Epub 2015 Mar 27.

PMID:
25819666
13.

Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.

Tongu M, Harashima N, Tamada K, Chen L, Harada M.

Cancer Sci. 2015 Jan;106(1):9-17. doi: 10.1111/cas.12568. Epub 2014 Dec 9.

14.

Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.

Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K, Harada M.

Oncotarget. 2014 Nov 30;5(22):11399-412.

16.

Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.

Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H.

Int Immunopharmacol. 2014 May;20(1):59-65. doi: 10.1016/j.intimp.2014.02.018. Epub 2014 Feb 26.

PMID:
24583149
17.

Pifithrin-μ, an inhibitor of heat-shock protein 70, can increase the antitumor effects of hyperthermia against human prostate cancer cells.

Sekihara K, Harashima N, Tongu M, Tamaki Y, Uchida N, Inomata T, Harada M.

PLoS One. 2013 Nov 14;8(11):e78772. doi: 10.1371/journal.pone.0078772. eCollection 2013.

18.

Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8.

Mishiro T, Kusunoki R, Otani A, Ansary MM, Tongu M, Harashima N, Yamada T, Sato S, Amano Y, Itoh K, Ishihara S, Kinoshita Y.

Lab Invest. 2013 Jul;93(7):834-43. doi: 10.1038/labinvest.2013.70. Epub 2013 Jun 10.

19.

The HSP70 and autophagy inhibitor pifithrin-μ enhances the antitumor effects of TRAIL on human pancreatic cancer.

Monma H, Harashima N, Inao T, Okano S, Tajima Y, Harada M.

Mol Cancer Ther. 2013 Apr;12(4):341-51. doi: 10.1158/1535-7163.MCT-12-0954. Epub 2013 Jan 31.

20.

Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.

Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, Harada M.

Cancer Immunol Immunother. 2013 Feb;62(2):383-91. doi: 10.1007/s00262-012-1343-0. Epub 2012 Aug 25.

PMID:
22926062
21.

Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice.

Tanaka K, Ishikawa S, Matsui Y, Kawanishi T, Tamesada M, Harashima N, Harada M.

Cancer Immunol Immunother. 2012 Nov;61(11):2143-52. doi: 10.1007/s00262-012-1275-8. Epub 2012 May 16.

PMID:
22588648
22.

Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer.

Inao T, Harashima N, Monma H, Okano S, Itakura M, Tanaka T, Tajima Y, Harada M.

Breast Cancer Res Treat. 2012 Jul;134(1):89-100. doi: 10.1007/s10549-011-1930-3. Epub 2011 Dec 28.

PMID:
22203435
23.

Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells.

Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M.

Cancer Immunol Immunother. 2012 May;61(5):667-76. doi: 10.1007/s00262-011-1132-1. Epub 2011 Oct 29.

PMID:
22038398
24.

Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression.

Tanaka K, Ishikawa S, Matsui Y, Tamesada M, Harashima N, Harada M.

Cancer Sci. 2011 Mar;102(3):516-21. doi: 10.1111/j.1349-7006.2010.01841.x. Epub 2011 Jan 25.

25.

Sterile' inflammation and autophagy in cancer immunotherapy.

Harada M, Harashima N.

Immunotherapy. 2010 Sep;2(5):599-601. doi: 10.2217/imt.10.55. No abstract available.

26.

Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma.

Tongu M, Harashima N, Yamada T, Harada T, Harada M.

Cancer Immunol Immunother. 2010 May;59(5):769-77. doi: 10.1007/s00262-009-0797-1. Epub 2009 Nov 26.

PMID:
19940990
27.

[Influence of commercial soft drinks or green tea intake to occult blood and sugar tests with urinalysis reagent strips].

Matsuo C, Harashima N, Sekine K, Kanou M, Kanazawa M, Ishikawa K, Nara Y, Ikeda H.

Rinsho Byori. 2009 Sep;57(9):834-41. Japanese.

PMID:
19860208
28.

Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies.

Kondo M, Murakawa Y, Harashima N, Kobayashi S, Yamaguchi S, Harada M.

Immunology. 2009 Sep;128(1 Suppl):e589-99. doi: 10.1111/j.1365-2567.2008.03039.x. Epub 2008 Dec 26.

29.

[Nutrition support team: the role of the medical technologist].

Harashima N.

Rinsho Byori. 2009 Aug;Suppl 144:101-2. Review. Japanese. No abstract available.

PMID:
22685785
30.

[Nutrition support team: the role of medical technologist].

Harashima N.

Rinsho Byori. 2009 Aug;Suppl 144:98-100. Review. Japanese. No abstract available.

PMID:
22685784
31.

Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages.

Shimizu Y, Takamori A, Utsunomiya A, Kurimura M, Yamano Y, Hishizawa M, Hasegawa A, Kondo F, Kurihara K, Harashima N, Watanabe T, Okamura J, Masuda T, Kannagi M.

Cancer Sci. 2009 Mar;100(3):481-9. doi: 10.1111/j.1349-7006.2008.01054.x. Epub 2008 Dec 16.

32.

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Tawab A, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW.

J Clin Invest. 2008 Mar;118(3):1099-109. doi: 10.1172/JCI34409. Erratum in: J Clin Invest. 2008 Apr;118(4):1584. Abdul, Tawab [corrected to Tawab, Abdul].

33.

Human T-cell leukemia virus type-I (HTLV-I)-specific T-cell responses detected using three-divided glutathione-S-transferase (GST)-Tax fusion proteins.

Kurihara K, Shimizu Y, Takamori A, Harashima N, Noji M, Masuda T, Utsunomiya A, Okamura J, Kannagi M.

J Immunol Methods. 2006 Jun 30;313(1-2):61-73. Epub 2006 May 4.

PMID:
16723135
34.

[Participation of medical technologists in the nutrition support team (NST)].

Harashima N, Muroya T, Shoji K, Sekine K, Ikeda H.

Rinsho Byori. 2005 Nov;53(11):1043-50. Japanese.

PMID:
16372756
35.
36.

Tumor immunity against adult T-cell leukemia.

Kannagi M, Harashima N, Kurihara K, Ohashi T, Utsunomiya A, Tanosaki R, Masuda M, Tomonaga M, Okamura J.

Cancer Sci. 2005 May;96(5):249-55. Review.

37.

Potential immunogenicity of adult T cell leukemia cells in vivo.

Kurihara K, Harashima N, Hanabuchi S, Masuda M, Utsunomiya A, Tanosaki R, Tomonaga M, Ohashi T, Hasegawa A, Masuda T, Okamura J, Tanaka Y, Kannagi M.

Int J Cancer. 2005 Mar 20;114(2):257-67.

38.

Immunological risks of adult T-cell leukemia at primary HTLV-I infection.

Kannagi M, Ohashi T, Harashima N, Hanabuchi S, Hasegawa A.

Trends Microbiol. 2004 Jul;12(7):346-52. Review.

PMID:
15223062
39.

Adult T-cell leukemia: future prophylaxis and immunotherapy.

Kannagi M, Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Masuda M.

Expert Rev Anticancer Ther. 2004 Jun;4(3):369-76. Review.

PMID:
15161436
40.

Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model.

Nomura M, Ohashi T, Nishikawa K, Nishitsuji H, Kurihara K, Hasegawa A, Furuta RA, Fujisawa J, Tanaka Y, Hanabuchi S, Harashima N, Masuda T, Kannagi M.

J Virol. 2004 Apr;78(8):3827-36.

41.

Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation.

Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T, Takaue Y, Okamura J, Kannagi M.

Cancer Res. 2004 Jan 1;64(1):391-9.

42.

Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients.

Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K.

Int J Cancer. 2002 May 20;99(3):409-17.

43.

Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients.

Tanaka K, Harashima N, Niiya F, Miyagi Y, Hida N, Ochi M, Imai N, Harada M, Itoh K, Shichijo S.

Jpn J Cancer Res. 2002 Feb;93(2):198-208.

PMID:
11856484
44.

Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases.

Imai N, Harashima N, Ito M, Miyagi Y, Harada M, Yamada A, Itoh K.

Int J Cancer. 2001 Oct 15;94(2):237-42.

45.

Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.

Tamura M, Nishizaka S, Maeda Y, Ito M, Harashima N, Harada M, Shichijo S, Itoh K.

Jpn J Cancer Res. 2001 Jul;92(7):762-7.

PMID:
11473727
46.

Molecular basis of T cell-mediated recognition of pancreatic cancer cells.

Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, Saito N, Itoh K.

Cancer Res. 2001 Mar 1;61(5):2038-46.

47.

Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.

Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Itoh K, Shichijo S.

Eur J Immunol. 2001 Feb;31(2):323-32.

PMID:
11180095
48.

Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.

Yamada A, Kawano K, Harashima N, Niiya F, Nagai K, Kobayashi T, Mine T, Ushijima K, Nishida T, Itoh K.

Cancer Immunol Immunother. 1999 May-Jun;48(2-3):147-52.

PMID:
10414469
49.

Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108.

Yamada A, Kubo K, Takeshita T, Harashima N, Kawano K, Mine T, Sagawa K, Sugamura K, Itoh K.

J Immunol. 1999 Apr 1;162(7):4094-100.

50.

ACTBP2 gene frequency distribution and sequencing of the allelic ladder and variants in the Japanese and Chinese populations.

Liu C, Harashima N, Katsuyama Y, Ota M, Arakura A, Fukushima H.

Int J Legal Med. 1997;110(4):208-12.

PMID:
9274946

Supplemental Content

Loading ...
Support Center